Solid Tumors, Unspecified

Open studies are marked with a purple background, closed studies have a grey background, studies to be opened have a white background
16041
Phase I trial of NGR-TNF administered every 3 weeks as a 1 hour intravenous infusion in patients with solid tumor.
16007
Phase I study to determine the safety of halofuginone in patients with a solid progressive tumor
13001
 Phase I clinical trial of recombinant viscumin ( rViscumin,rMistletoe lectin,rML) administered twice weekly by the subcutaneous route in patients with solid tumors after failure of standard therapy
16002
 Phase I clinical trial of recombinant mistletoe lectin (rML,rViscumin) administered twice weekly by the intravenous route in patients with solid tumors after failure of standard chemotherapy
13992
 A phase I, open label multiple dose, safety and pharmacokinetic study of intravenously administered humanized anti-VEGF monoclonal antibody (HuMV833) to patients with relapsed or refractory solid tumors.
16992
Phase I study to determine the safety of MS-209 in combination with docetaxel in patients with a solid progressive tumor

Back to Site-list